| 產(chǎn)品編號 | bs-1704R-Cy5 |
| 英文名稱 | Rabbit Anti-PAI1/Cy5 Conjugated antibody |
| 中文名稱 | Cy5標記的纖溶酶原激活物抑制因子抗體 |
| 別 名 | Clade E; Endothelial plasminogen activator inhibitor; Nexin; PAI 1; PAI; PAI-1; PAI1_HUMAN; PLANH1; Plasminogen activator inhibitor 1; Plasminogen activator inhibitor type 1; Serine (or cysteine) proteinase inhibitor; Serine (or cysteine) proteinase inhibitor clade E (nexin plasminogen activator inhibitor type 1) member 1; Serpin E1; Serpin peptidase inhibitor clade E (nexin plasminogen activator inhibitor type 1) member 1; Serpin peptidase inhibitor clade E; Serpine 1; Serpine1. |
| 規(guī)格價格 | 100ul/2980元 購買 大包裝/詢價 |
| 說 明 書 | 100ul |
| 研究領域 | 腫瘤 心血管 細胞生物 |
| 抗體來源 | Rabbit |
| 克隆類型 | Polyclonal |
| 交叉反應 | (predicted: Human, Mouse, Rat, Dog, Pig, Cow, Rabbit, Sheep, ) |
| 產(chǎn)品應用 | IF=1:50-200
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 43kDa |
| 性 狀 | Lyophilized or Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human PAI-1 |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 儲 存 液 | 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| 保存條件 | Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. |
| 產(chǎn)品介紹 |
background: PAI1 (plasminogen activator inhibitor 1) is originally cloned from human endothelial cell (Pannekoek 1986, Ginsburg 1986) and rat hepatoma cell 3 cDNA libraries. As a member of the serpin family of serine protease inhibitors, PAI1 inhibits both tissue type plasminogen activator (tPA) and urokinase type plasminogen activator (uPA). High PAI1 levels are associated with an increased risk of thromboembolic disease while PAI1 deficiency may represent an inherited autosomal recessive bleeding disorder. Function: Serine protease inhibitor. This inhibitor acts as 'bait' for tissue plasminogen activator, urokinase, protein C and matriptase-3/TMPRSS7. Its rapid interaction with PLAT may function as a major control point in the regulation of fibrinolysis. Subunit: Forms protease inhibiting heterodimer with TMPRSS7. Interacts with VTN. Binds LRP1B; binding is followed by internalization and degradation. Subcellular Location: Secreted Tissue Specificity: Found in plasma and platelets and in endothelial, hepatoma and fibrosarcoma cells Post-translational modifications: Inactivated by proteolytic attack of the urokinase-type (u-PA) and the tissue-type (TPA), cleaving the 369-Arg-|-Met-370 bond. DISEASE: Plasminogen activator inhibitor-1 deficiency (PAI-1D) [MIM:613329]: A hematologic disorder characterized by increased bleeding after trauma, injury, or surgery. Affected females have menorrhagia. The bleeding defect is due to increased fibrinolysis of fibrin blood clots due to deficiency of plasminogen activator inhibitor-1, which inhibits tissue and urinary activators of plasminogen. Note=The disease is caused by mutations affecting the gene represented in this entry. Note=High concentrations of SERPINE1 seem to contribute to the development of venous but not arterial occlusions. Similarity: Belongs to the serpin family Database links: Entrez Gene: 5054 Human Entrez Gene: 18787 Mouse Omim: 173360 Human SwissProt: P05121 Human SwissProt: P22777 Mouse Unigene: 414795 Human Unigene: 713079 Human Unigene: 250422 Mouse Unigene: 29367 Rat Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. PAI-1是一種單鏈糖蛋白，其生理作用很多： （1）與組織型纖溶酶原激活物（tissue plasminogen activator，t-PA）形成1：1的復合物而使t-PA失活; （2）保護基底膜不被血漿來源的酶所降解; （3）保護細胞間的接觸面而維持組織結(jié)構(gòu)的完整性; （4）在結(jié)締組織演變、凝血、纖溶、補體激活和炎癥反應等過程中具有抑制蛋白降解作用; （5）在細胞周期中，PAI-1轉(zhuǎn)錄水平的變化及其在細胞內(nèi)的積聚，對細胞形態(tài)的維持、細胞與其間質(zhì)的粘附、細胞增殖、信號轉(zhuǎn)導及基因表達等都有重要意義; |
| 1、抗體溶解方法 | |
| 2、抗體修復方式 | |
| 3、常用試劑的配制 | |
| 4、免疫組化操作步驟 | |
| 5、免疫組化問題解答 | |
| 6、Western Blotting 操作步驟 | |
| 7、Western Blotting 問題解答 | |
| 8、關于肽鏈的設計 | |
| 9、多肽的溶解與保存 | |
| 10、酶標抗體效價測定程序 | |
